For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| In-process research and development | 0 | 10,000 | ||
| Research and development | 9,127 | 6,743 | ||
| General and administrative | 5,895 | 6,157 | ||
| Restructuring and impairment charges | 0 | 540 | ||
| Total operating expenses | 15,022 | 23,440 | ||
| Loss from operations | -15,022 | -23,440 | ||
| Interest income | 893 | 1,044 | ||
| Interest expense | 1,582 | 1,582 | ||
| Other rental income | 2,242 | 2,242 | ||
| Other expense, net | -118 | 342 | ||
| Net loss | -13,587 | -21,394 | ||
| Foreign currency translation | 122 | -314 | ||
| Unrealized gain (loss) on available-for-sale securities, net | 71 | -40 | ||
| Net comprehensive loss | -13,394 | -21,748 | ||
| Basic EPS | -2.01 | -3.24 | ||
| Diluted EPS | -2.01 | -3.24 | ||
| Basic Average Shares | 6,757,742 | 6,596,975 | ||
| Diluted Average Shares | 6,757,742 | 6,596,975 | ||
Instil Bio, Inc. (TIL)
Instil Bio, Inc. (TIL)